Literature DB >> 12769665

Drug uptake systems in liver and kidney.

J E van Montfoort1, B Hagenbuch, G M M Groothuis, H Koepsell, P J Meier, D K F Meijer.   

Abstract

The hepatobiliary system and the kidneys are the main routes by which drugs and their metabolites leave the body. Compounds that are mainly excreted into bile in general have relatively high molecular weights, are amphipathic and highly bound to plasma proteins. In contrast, compounds that are predominantly excreted into urine have relatively low molecular weights, are more hydrophilic and generally less protein bound. The first step in drug elimination in liver and kidney is uptake into hepatocytes or into proximal tubular cells. The substrate specificity and affinity of the uptake carriers expressed at the basolateral membranes of hepatocytes and proximal tubular cells could therefore play an important role for the determination of the main elimination route of a compound. This review discusses the tissue distribution, substrate specificity, transport mechanism, and regulation of the members of the organic anion transporting polypeptide (Oatp/OATP) superfamily (solute carrier family SLC21A) and the SLC22A family containing transporters for organic cations (OCTs) and organic anions (OATs). The Oatps/OATPs are mainly important for the hepatic uptake of large amphipathic organic anions, organic cations and uncharged substrates, whereas OCTs and OATs mediate uptake of predominantly small organic cations and anions in liver and kidney.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12769665     DOI: 10.2174/1389200033489460

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  39 in total

Review 1.  The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions.

Authors:  Lawrence M DuBuske
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Regulation of organic cation transport.

Authors:  Giuliano Ciarimboli; Eberhard Schlatter
Journal:  Pflugers Arch       Date:  2004-11-16       Impact factor: 3.657

Review 3.  Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.

Authors:  Ahsan N Rizwan; Gerhard Burckhardt
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 4.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

Review 5.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

6.  Estimation of biliary excretion of foreign compounds using properties of molecular structure.

Authors:  Mohsen Sharifi; Taravat Ghafourian
Journal:  AAPS J       Date:  2013-11-08       Impact factor: 4.009

7.  Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.

Authors:  Katherine S Lovejoy; Stephen J Lippard
Journal:  Dalton Trans       Date:  2009-10-01       Impact factor: 4.390

8.  A comparison between the effects of ochratoxin A and aristolochic acid on the inflammation and oxidative stress in the liver and kidney of weanling piglets.

Authors:  D E Marin; G C Pistol; M Gras; M Palade; I Taranu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-22       Impact factor: 3.000

9.  Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.

Authors:  Mark D Erion; Edward E Cable; Bruce R Ito; Hongjian Jiang; James M Fujitaki; Patricia D Finn; Bao-Hong Zhang; Jinzhao Hou; Serge H Boyer; Paul D van Poelje; David L Linemeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-18       Impact factor: 11.205

10.  Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.

Authors:  Woo Kyun Bae; Jongun Lee; Jeong Woo Park; Eun Hui Bae; Seong Kwon Ma; Suhn Hee Kim; Soo Wan Kim
Journal:  Korean J Physiol Pharmacol       Date:  2008-12-31       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.